Radiopharmaceuticals for imaging and endoradiotherapy of neurotensin receptor-positive tumors

Maschauer S, Prante O (2017)

Publication Type: Journal article

Publication year: 2017

Journal

Journal of Labelled Compounds & Radiopharmaceuticals Wiley-Blackwell

DOI: 10.1002/jlcr.3581

Abstract

The neurotensin receptors are overexpressed in various tumor types, especially in highly progressive pancreatic tumors. As this cancer has a poor 5-year survival prognosis, there is an urgent need to improve early diagnosis and treatment strategies. This review article provides an overview of the latest developments in radiopharmaceuticals for neurotensin receptor-positive tumors, including peptidic and non-peptidic radiopharmaceuticals, not only for SPECT and PET but also for endoradiotherapy.

Authors with CRIS profile

Simone Maschauer Department of Nuclear Medicine Olaf Prante Professur für Molekulare Bildgebung und Radiochemie

How to cite

APA:

Maschauer, S., & Prante, O. (2017). Radiopharmaceuticals for imaging and endoradiotherapy of neurotensin receptor-positive tumors. Journal of Labelled Compounds & Radiopharmaceuticals. https://doi.org/10.1002/jlcr.3581

MLA:

Maschauer, Simone, and Olaf Prante. "Radiopharmaceuticals for imaging and endoradiotherapy of neurotensin receptor-positive tumors." Journal of Labelled Compounds & Radiopharmaceuticals (2017).

BibTeX: Download